BioVersys AG researches and develops antimicrobial drugs for bacterial infections. It develops BV100 that is in Phase 3 clinical trial for carbapenem-resistant Acinetobacter baumannii lung and bloodstream infections. The company is also developing Alpibectir, which is in Phase 2 clinical trial for the treatment of pulmonary and meningeal tuberculosis; BV200 to treat patients with Gram-positive S. aureus; and BV500 for non-tuberculous mycobacteria infections. It has a research and license option agreement with Shionogi & Co., Ltd. to develop ansamycin leads from the BV500 program into clinical candidates. The company was founded in 2008 and is based in Basel, Switzerland.
Metrics to compare | BIOV | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBIOVPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.4x | 5.2x | −0.5x | |
PEG Ratio | −0.24 | 0.00 | 0.00 | |
Price/Book | 2.7x | 0.9x | 2.6x | |
Price / LTM Sales | 49.2x | 2.0x | 3.1x | |
Upside (Analyst Target) | 125.1% | 50.1% | 58.4% | |
Fair Value Upside | Unlock | 18.6% | 9.3% | Unlock |